RELAPSE IN ACUTE MYELOID LEUKAEMIA (AML) WITH INV16 OR T(16;16) MAY OFTEN BE SLOW, AS SHOWN BY SEQUENTIAL RQ-PCR ANALYSES

被引：0
|
作者：
Venot, M. [1 ]
Renneville, A. [2 ]
Gardin, C. [1 ]
Kelaidi, C. [1 ]
Leroux, G. [3 ]
Eclache, V. [3 ]
Preudhomme, C. [2 ]
Fenaux, P. [1 ]
Ades, L. [1 ]
机构：
[1] Univ Paris 13, Hop Avicenne, AP HP, Bobigny, France
[2] Inst Rech Canc, INSERM, U837, Lab Hematol A, Lille, France
[3] Hop Avicenne Hematol Biol, Bobigny, France
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2008年 / 93卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0979
引用
收藏
页码：390 / 390
页数：1
相关论文
共 25 条
  • [1] Slow relapse in acute myeloid leukemia with inv(16) or t(16;16)
    Clozel, Thomas
    Renneville, Aline
    Venot, Marion
    Gardui, Claude
    Kelaidi, Charikleia
    Leroux, Genevieve
    Eclache, Virginie
    Preudhomme, Claude
    Fenaux, Pierre
    Ades, Lionel
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 (10): : 1466 - 1468
  • [2] Indolent course of molecular relapse in AML inv(16) as measured by RQ-PCR - A new window of opportunity for early intervention?
    Stentoft, J
    Ostergaard, M
    Hokland, P
    BLOOD, 2003, 102 (11) : 225B - 225B
  • [3] RQ-PCR used for serial monitoring of minimal residual disease in AML t(8;21) and inv(16).
    Stentoft, J
    Ostergaard, M
    Hokland, P
    BLOOD, 2003, 102 (11) : 225B - 225B
  • [4] Detection of 16 p deletions by FISH in patients with inv(16) or t(16;16) and acute myeloid leukemia (AML)
    Martinet, D
    Muhlematter, D
    Leeman, M
    Parlier, V
    Hess, U
    Gmur, J
    Jotterand, M
    LEUKEMIA, 1997, 11 (07) : 964 - 970
  • [5] Detection of 16 p deletions by FISH in patients with inv(16) or t(16;16) and acute myeloid leukemia (AML)
    D Martinet
    D Mühlematter
    M Leeman
    V Parlier
    U Hess
    J Gmür
    M Jotterand
    Leukemia, 1997, 11 : 964 - 970
  • [6] Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML):: a survey of 110 cases from the French AML Intergroup
    Delaunay, J
    Vey, N
    Leblanc, T
    Fenaux, P
    Rigal-Huguet, F
    Witz, F
    Lamy, T
    Auvrignon, A
    Blaise, D
    Pigneux, A
    Mugneret, F
    Bastard, C
    Dastugue, N
    Van den Akker, J
    Fière, D
    Reiffers, J
    Castaigne, S
    Leverger, G
    Harousseau, JL
    Dombret, H
    BLOOD, 2003, 102 (02) : 462 - 469
  • [7] Common gene expression signatures in t(8;21)- and inv(16)-acute myeloid leukaemia
    Ichikawa, Hitoshi
    Tanabe, Kenji
    Mizushima, Hiroshi
    Hayashi, Yasuhide
    Mizutani, Shuki
    Ishii, Eiichi
    Hongo, Teruaki
    Kikuchi, Akira
    Satake, Masanobu
    BRITISH JOURNAL OF HAEMATOLOGY, 2006, 135 (03) : 336 - 347
  • [8] Prognostic implication of additional cytogenetic aberrations in de novo acute myeloid leukemia (AML) with t(15;17), t(8;21) or inv(16)/t(16;16).
    Wiernik, PH
    Kim, H
    Gundacker, H
    Dewald, G
    Slovak, ML
    Paietta, E
    Appelbaum, FR
    Tallman, MS
    BLOOD, 2001, 98 (11) : 457A - 457A
  • [9] Gene expression profiling (GEP) in de novo pediatric acute myeloid leukemia (AML) patients reveals a robust expression signature that correlates with inv(16) and t(16;16).
    Lacayo, N
    Kinnunen, P
    Raimondi, SC
    Yu, R
    Wahab, R
    Stuber, C
    Douglas, L
    Chang, M
    Willman, CL
    Ravindranath, Y
    Weinstein, H
    Becton, D
    Behm, F
    Tibshirani, R
    Sikic, BI
    Dahl, GV
    BLOOD, 2003, 102 (11) : 365A - 365A
  • [10] Type and Number of Secondary Molecular Lesions Improve Outcome Prediction in Acute Myeloid Leukemia (AML) with inv(16) or t(16;16): A Study of the German-Austrian AML Study Group (AMLSG)
    Paschka, Peter
    Du, Juan
    Schlenk, Richard F.
    Gaidzik, Verena I.
    Bullinger, Lars
    Corbacioglu, Andrea
    Zucknick, Manuela
    Benner, Axel
    Stegelmann, Frank
    Spaeth, Daniela
    Kayser, Sabine
    Schlegelberger, Brigitte
    Krauter, Juergen
    Ganser, Arnold
    Doehner, Hartmut
    Doehner, Konstanze
    BLOOD, 2009, 114 (22) : 340 - 340
123